Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Blood (2017) 130 (24): 2610–2618.

https://doi.org/10.1182/blood-2017-06-791228

Published: 2017

Includes: Supplemental data

Journal Articles

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2016) 128 (22): 243.

https://doi.org/10.1182/blood.V128.22.243.243

Published: 2016

Journal Articles

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Blood (2015) 126 (23): 811.

https://doi.org/10.1182/blood.V126.23.811.811

Published: 2015

Journal Articles

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Blood (2014) 124 (21): 3414.

https://doi.org/10.1182/blood.V124.21.3414.3414

Published: 2014

Journal Articles

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Vishal Kukreti, Robert A. Vescio, Lixia Pei, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, Raymond L. Comenzo

Blood (2014) 124 (16): 2498–2506.

https://doi.org/10.1182/blood-2014-04-568329

Published: 2014

Includes: Supplemental data

Journal Articles

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Blood (2014) 123 (10): 1461–1469.

https://doi.org/10.1182/blood-2013-07-517276

Published: 2014

Journal Articles

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Blood (2014) 123 (5): 632–639.

https://doi.org/10.1182/blood-2013-05-504340

Published: 2014

Includes: Supplemental data

Journal Articles

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Blood (2013) 122 (21): 3187.

https://doi.org/10.1182/blood.V122.21.3187.3187

Published: 2013

Journal Articles

Suppression Of Uninvolved Immunoglobulin Has Significant Clinical Implication Including Predicting Relapse In Multiple Myeloma

Saulius Girnius, M.D., Rachel Neuwirth, Ph.D, Dixie-Lee Esseltine, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Munshi C Nikhil, MD

Blood (2013) 122 (21): 3151.

https://doi.org/10.1182/blood.V122.21.3151.3151

Published: 2013

Journal Articles

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Blood (2012) 120 (23): 4513–4516.

https://doi.org/10.1182/blood-2012-05-426924

Published: 2012

Includes: Supplemental data

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Philippe Moreau, MD, Ievgenii I Karamanesht, MD, Natalia Domnikova, Maryna Y Kyselyova, MD, Kateryna Vilchevska, Vadim A Doronin, MD, PhD, Alexander Schmidt, MD, Cyrille Hulin, MD, Xavier Leleu, MD, PhD, Dixie-Lee Esseltine, MD, FRCPC, Karthik Venkatakrishnan, Donna M Skee, BS, Huaibao Feng, PhD, Suzette Girgis, Andrew Z Cakana, MD, FRCPath, William M Deraedt, PhD, Thierry Facon, MD

Blood (2011) 118 (21): 1863.

https://doi.org/10.1182/blood.V118.21.1863.1863

Published: 2011

Journal Articles

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Jesús F San Miguel, MD PhD, Paul G. Richardson, MD, Robert Z. Orlowski, MD, PhD, Hartmut Goldschmidt, Deyanira Corzo, MD, Carol Satler, Dixie-Lee Esseltine, MD, FRCPC, Rachel Neuwirth, MS, Maria Ponsillo, MD, Andrew Z Cakana, MD, FRCPath, Jay King, MD, William M Deraedt, PhD, Avinash Desai, Yana Lutska, Dina Gifkins, PhD, Kevin Liu, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 2933.

https://doi.org/10.1182/blood.V118.21.2933.2933

Published: 2011

Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Blood (2011) 118 (21): 265.

https://doi.org/10.1182/blood.V118.21.265.265

Published: 2011

Journal Articles

Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,

Dina Gifkins, PhD, Megan McAuliffe, ScD, Amy Matcho, BS, Jane Porter, MS, Scott Chavers, PhD, Maria Ponsillo, MD, Jay King, MD, Avinash Desai, MD, Andrew Cakana, MD, Dixie-Lee Esseltine, MD

Blood (2011) 118 (21): 3972.

https://doi.org/10.1182/blood.V118.21.3972.3972

Published: 2011

Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS

Blood (2011) 118 (21): 1377.

https://doi.org/10.1182/blood.V118.21.1377.1377

Published: 2011

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Robert A. Vescio, Kevin Liu, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, Raymond L. Comenzo

Blood (2011) 118 (4): 865–873.

https://doi.org/10.1182/blood-2011-02-334227

Published: 2011

Includes: Supplemental data

Journal Articles

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Blood (2011) 118 (3): 535–543.

https://doi.org/10.1182/blood-2011-02-334755

Published: 2011

Journal Articles

Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle

Pooja S. Raibagkar, MD, Paul G Richardson, Pieter Sonneveld, Michael W. Schuster, MD, David Irwin, MD, Edward A. Stadtmauer, MD, Thierry Facon, MD, Jean-Luc Harousseau, MD, Dina Ben-Yehuda, Sagar Lonial, MD, Hartmut Goldschmidt, Donna E. Reece, MD, Jesus F San Miguel, Joan Blade, Mario Boccadoro, Rachel Neuwirth, MS, Dixie-Lee Esseltine, MD, FRCPC, Kenneth C. Anderson, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 1963.

https://doi.org/10.1182/blood.V116.21.1963.1963

Published: 2010

Journal Articles

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

Blood (2010) 116 (21): 1937.

https://doi.org/10.1182/blood.V116.21.1937.1937

Published: 2010

NARROW

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Suppression Of Uninvolved Immunoglobulin Has Significant Clinical Implication Including Predicting Relapse In Multiple Myeloma

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only